TY - JOUR
T1 - Chronic 1,4-butanediol treatment in rats
T2 - Cross-tolerance to γ-hydroxybutyrate and (±)-baclofen
AU - Eckermann, Kary A.
AU - Koek, Wouter
AU - France, Charles P.
N1 - Funding Information:
Supported by USPHS DA14986 and RCA DA0211 (CPF). The authors thank Dr. L.R. McMahon and L.P. Carter for helpful suggestions as well as C. Cruz, H. Renteria, D. Mojica, and G. Phillips for excellent technical assistance.
PY - 2004/1/26
Y1 - 2004/1/26
N2 - The effects of 1,4-butanediol, γ-hydroxybutyrate (GHB), and (±)-baclofen on food-maintained responding in rats were assessed before, during, and after chronic treatment with 1,4-butanediol. Six weeks of treatment with 1,4-butanediol (twice daily, 320 mg/kg for 3 weeks followed by 560 mg/kg for 3 weeks) decreased sensitivity to the rate-decreasing effects of (±)-baclofen and GHB without changing sensitivity to 1,4-butanediol. Sensitivity to (±)-baclofen and GHB returned to control values 2-3 weeks after discontinuation of treatment. These data suggest that tolerance to the effects of GHB or its precursors might result from changes in GABAB mechanisms.
AB - The effects of 1,4-butanediol, γ-hydroxybutyrate (GHB), and (±)-baclofen on food-maintained responding in rats were assessed before, during, and after chronic treatment with 1,4-butanediol. Six weeks of treatment with 1,4-butanediol (twice daily, 320 mg/kg for 3 weeks followed by 560 mg/kg for 3 weeks) decreased sensitivity to the rate-decreasing effects of (±)-baclofen and GHB without changing sensitivity to 1,4-butanediol. Sensitivity to (±)-baclofen and GHB returned to control values 2-3 weeks after discontinuation of treatment. These data suggest that tolerance to the effects of GHB or its precursors might result from changes in GABAB mechanisms.
KW - (±)-Baclofen
KW - 1,4-Butanediol
KW - Cross-tolerance
KW - GABA receptor
KW - γ-GHB (γ-hydroxybutyrate)
UR - http://www.scopus.com/inward/record.url?scp=1642505607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642505607&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2003.11.016
DO - 10.1016/j.ejphar.2003.11.016
M3 - Article
C2 - 14744611
AN - SCOPUS:1642505607
VL - 484
SP - 259
EP - 262
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 2-3
ER -